ClinicalTrials.gg
Active, not recruitingNCT04246086Updated Sep 14, 2026

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

A Phase 1/2 interventional study of Mosunetuzumab (IV) and Tocilizumab in Follicular Lymphoma, sponsored by Hoffmann-La Roche. Active, not recruiting at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.

Planned enrollment
4th of 17
237 · median 42
Started
2020
the only one that year
Phase 1/2
2 of 17
none open now
Primary completion
2030-09
later than 11 of 14 live
Registered
1st of 17
by date
Lead sponsor
3 of 17
Hoffmann-La Roche

Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 4th largest by planned enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 14 other live ones, and was the 1st registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mosunetuzumab

mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing mosunetuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.

03

Conditions studied

  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0, 1, or 2
  • R/R FL after treatment with at least one prior systemic lymphoma therapy, which includes prior immunotherapy or chemoimmunotherapy
  • Previously untreated participants with FL must require systemic therapy assessed by investigator based on the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria and have a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5
  • documented FL of Grade 1, 2, or 3a, and that expresses CD20 at time of diagnosis as determined by the local laboratory
  • Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma)
  • At least one bi dimensionally measurable nodal lesion (>1.5 cm in its largest dimension by PET- computed tomography (CT) scan), or at least one bi dimensionally measurable extranodal lesion (>1.0 cm in its largest dimension by PET-CT scan)
  • Availability of a representative tumor specimen and the corresponding pathology report for confirmation of the diagnosis of FL
  • Adequate hematologic function (unless due to underlying lymphoma, per the investigator) as defined by the protocol
  • Negative test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a ≥ 200/mL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
  • Normal laboratory values (unless due to underlying lymphoma) as defined by the protocol
  • Agreement to comply with all local requirements of the Len risk minimization plan
  • For women of : agreement to remain abstinent or use two adequate methods of , including at least one method with a failure rate of \< 1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period, and for at least 12 months after the final dose of glofitamab, 28 days after the last dose of Len, 18 months after the last dose of G, 3 months after the final dose of tocilizumab, and 3 months after the final dose of Mosun. Women must refrain from donating eggs during this same period
  • For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm, with female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 2 months after the final dose of glofitamab, 28 days after last dose of Len, 18 months after the last dose of G, 3 months after the final dose of tocilizumab, and 3 months after the final dose of Mosun

Exclusion criteria

Exclusion Criteria

  • Any history of Grade 3b FL
  • Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment
  • Any history of disease transformation and/or diffuse large B-cell lymphoma (DLBCL)
  • Documented refractoriness to an obinutuzumab monotherapy containing regimen in glofitamab-containing treatment combination
  • Active or history of central nervous system (CNS) lymphoma or infiltration
  • Documented refractoriness to lenalidomide, defined as no response (partial response (PR) or complete response (CR)) within 6 months of therapy
  • Prior standard or anti-cancer therapy as specified by the protocol
  • toxicity (other than alopecia) from prior treatment that has not resolved to Grade \<=2 prior to Day 1 of Cycle 1
  • Known history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis or evidence of active pneumonitis on screening chest CT scan
  • Treatment with systemic medications, including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1
  • History of solid organ transplantation
  • History of severe allergic or anaphylactic reaction to humanized, chimeric or murine MAbs
  • Known sensitivity or allergy to murine products
  • Known to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the glofitamab, Mosun, G, Len, or thalidomide formulation, including mannitol
  • History of erythema multiforme, Grade >=3 rash, or blistering following prior treatment with immunomodulatory derivatives
  • Known history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis or evidence of active pneumonitis on screening chest CT scan
  • Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1
  • Known or suspected chronic active Epstein-Barr virus infection or hemophagocytic syndrome
  • Known history of macrophage activating syndrome (MAS) or hemophagocytic lymphohistiocytosis (HLH)
  • Active and infection or disease requiring treatment
  • Prior allogenic hematopoietic stem cell transplant
  • Known history of positive status
  • History of progressive multifocal leukoencephalopathy
  • Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a will be required during the study
  • Other that could affect compliance with the protocol or interpretation of results
  • Prior allogenic hematopoietic stem cell transplant ()
  • to treatment for thromboembolism prophylaxis
  • Grade >=2 neuropathy
  • Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to significant cardiovascular disease or significant pulmonary disease
  • Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Inadequate hematologic function
  • Any of the following abnormal laboratory values
  • Pregnant or lactating or intending to become pregnant during the study
  • \< 3 months
  • Unable to comply with the study protocol, in the investigator's judgment
  • History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
237 participants (estimated)

Study arms

  • Experimental
    Intravenous (IV) Mosunetuzumab + Lenalidomide (Non-randomized)

    Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)

    Drug: Mosunetuzumab (IV) · Drug: Tocilizumab · Drug: Lenalidomide

  • Experimental
    Subcutaneous (SC) Mosunetuzumab + Lenalidomide (Non-randomized)

    Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward). Participants that have received complete metabolic response (CMR) or partial metabolic response (PMR) after 12 cycles of induction therapy with mosunetuzumab + lenalidomide will receive maintenance therapy with SC mosunetuzumab every 8 weeks (Q8W) for an additional 9 cycles.

    Drug: Tocilizumab · Drug: Lenalidomide

  • Experimental
    Arm A: IV Mosunetuzumab + Len (Randomized)

    Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)

    Drug: Mosunetuzumab (IV) · Drug: Lenalidomide

  • Experimental
    Arm B: SC Mosunetuzumab + Len (Randomized)

    Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)

    Drug: Lenalidomide · Drug: Mosunetuzumab (SC)

Interventions

  • Participants will receive IV mosunetuzumab as defined by the study protocol

    Also known as: RO7030816

  • Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol

    Also known as: RO4877533

  • Participants will receive oral lenalidomide as defined by the study protocol

  • Participants will receive SC mosunetuzumab as defined by the study protocol

    Also known as: RO7030816

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicities (DLTs)

    Time frame: Cycle 2 Days 1-28 (cycle length = 28 days)

  2. Percentage of Participants with Adverse Events

    Time frame: From baseline to 90 days after the last dose of study drug

  3. Cumulative Area under the Curve over Cycles 1-3 (AUC1-3) of Mosunetuzumab

    Time frame: Day 1 - Day 78

  4. Serum Trough Concentration at Steady State Approximated by Cycle 4 (Ctrough, c4) of Mosunetuzumab

    Time frame: Day 106

  5. Overall Response Rate (ORR) as Determined by the Independent Review Committee (IRC)

    Time frame: Up to the end of Cycle 12 (cycle length = 28 days)

Secondary outcomes

  1. Complete Response Rate (CRR) as determined by the investigator (non-randomized stage)

    Time frame: Up to the end of Cycle 12 (cycle length = 28 days)

  2. CRR as determined by Independent Review Committee (IRC) (randomized stage)

    Time frame: Up to the end of Cycle 12 (cycle length = 28 days)

  3. Objective Response Rate (ORR) as determined by the investigator (non-randomized stage)

    Time frame: Up to the end of Cycle 12 (cycle length = 28 days)

  4. ORR as determined by IRC (randomized stage)

    Time frame: Up to the end of Cycle 12 (cycle length = 28 days)

  5. Duration of Response (DOR) as determined by the investigator (non-randomized stage)

    Time frame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, up to the end of Cycle 8 (cycle length = 28 days)

  6. DOR as determined by IRC (randomized stage)

    Time frame: From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, up to the end of Cycle 8 (cycle length = 28 days)

  7. Duration of Complete Reponse (DOCR) as determined by the investigator (non-randomized stage)

    Time frame: From the first occurrence of a documented complete response (CR) to disease progression, relapse, or death from any cause, whichever occurs first, up to the end of Cycle 12 (cycle length = 28 days)

  8. DOCR as determined by IRC (randomized stage)

    Time frame: From the first occurrence of a documented complete response (CR) to disease progression, relapse, or death from any cause, whichever occurs first, up to the end of Cycle 12 (cycle length = 28 days)

  9. Percentage of Participants with AEs (Arms A and B)

    Time frame: From baseline to 90 days after the last dose of study drug

  10. Minimum Serum Concentration (Cmin) of Mosunetuzumab

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)

  11. Maximum Serum Concentration (Cmax) of Mosunetuzumab

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)

  12. Cumulative AUC Over Cycles 1-2 (AUCc1-2) of Mosunetuzumab (Arms A and B)

    Time frame: Day 1 - Day 50

  13. Serum Trough Concentration in Cycle 2 (Ctrough, c2) of Mosunetuzumab (Arms A and B)

    Time frame: Day 50

  14. AUC at Steady State (AUCss) (Arms A and B)

    Time frame: Cycle 4 (cycle length = 28 days)

  15. Percentage of Participants with ADAs to Mosunetuzumab

    Time frame: At pre-defined intervals from baseline through follow-up (2 years after last treatment)

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Sep 2030, 120 months after the start.

Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's planned 120 months is above that.

Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 29, 2020
StartActual
Aug 12, 2020
Primary completionEst.
Sep 6, 2030
CompletionEst.
Sep 6, 2030
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04246086
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Aug 12, 2020
Primary completion
Sep 6, 2030 (estimated)
Completion
Sep 6, 2030 (estimated)
Last update
Sep 14, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosunetuzumab

Start the discussion